Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 12, 2014, Pages 1991-1995

  Tuomi, Heidi ^a   Kultti, Johanna ^a   Danielsson, Joanna ^a   Kangastupa, Päivikki ^a   Åkerman, Kari ^a   Niemelä, Onni ^a  

^a SEINÄJOKI CENTRAL HOSPITAL   (Finland)

Author keywords

Ethanol; Fibrosis; Liver; Prognosis; suPAR

Indexed keywords

HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FIBROGENESIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; DIFFERENTIAL DIAGNOSIS; DRINKING BEHAVIOR; FIBROSIS; LIVER; LIVER DISEASES, ALCOHOLIC; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

ADULT; ALCOHOL DRINKING; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROSIS; HUMANS; LIVER; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SOLUBILITY;

EID: 84919693043     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12639     Document Type: Article

References (44)

1. Lieber CS. Medical disorders of alcoholism. N. Engl. J. Med. 1995; 333: 1058-1065.
2. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005; 365: 519-530.
3. Bataller R, Brenner DA. Liver fibrosis. J. Clin. Invest. 2005; 115: 209-218.
4. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
5. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004; 10: 429-434.
6. Friedman SL. Liver fibrosis-from bench to bedside. J. Hepatol. 2003; 38 (Suppl. 1): S38-53.
7. Ghany MG, Doo E. Assessment of liver fibrosis: palpate, poke or pulse? Hepatology 2005; 42: 759-761.
8. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-147.
9. Kamal SM, Turner B, He Q etal. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006; 43: 771-779.
10. McCullough AJ, Stassen WN, Wiesner RH, Czaja AJ. Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology 1987; 7: 49-54.
11. Niemelä O, Risteli L, Sotaniemi EA, Risteli J. Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease. Gastroenterology 1983; 85: 254-259.
12. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev. Mol. Diagn. 2005; 5: 15-21.
13. Niemelä O, Risteli J, Blake JE, Risteli L, Compton KV, Orrego H. Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake. Gastroenterology 1990; 98: 1612-1619.
14. Nøjgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J. Hepatol. 2003; 39: 179-186.
15. Rosman AS, Lieber CS. Diagnostic utility of laboratory tests in alcoholic liver disease. Clin. Chem. 1994; 40: 1641-1651.
16. Torres-Salinas M, Parés A, Caballería J etal. Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology 1986; 90: 1241-1246.
17. Trinchet JC, Hartmann DJ, Pateron D etal. Serum type I collagen and N-terminal peptide of type III procollagen in patients with alcoholic liver disease: relationship to liver histology. Alcohol. Clin. Exp. Res. 1992; 16: 342-346.
18. Stickel F, Urbaschek R, Schuppan D etal. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig. Dis. Sci. 2001; 46: 2025-2032.
19. Stickel F, Poeschl G, Schuppan D etal. Serum hyaluronate correlates with histological progression in alcoholic liver disease. Eur. J. Gastroenterol. Hepatol. 2003; 15: 945-950.
20. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J. Med. Virol. 2008; 80: 209-216.
21. Koch A, Voigt S, Kruschinski C etal. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit. Care 2011; 15: R63.
22. Thunø M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis. Markers 2009; 27: 157-172.
23. Eugen-Olsen J. suPAR-a future risk marker in bacteremia. J. Intern. Med. 2011; 270: 29-31.
24. Uusitalo-Seppälä R, Huttunen R, Tarkka M etal. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J. Intern. Med. 2012; 272: 247-256.
25. Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2012; 32: 500-509.
26. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J. Clin. Gastroenterol. 2012; 46: 334-338.
27. Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983; 3: 896-905.
28. Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92: 208-214.
29. Bode C, Bode JC. Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol. Clin. Exp. Res. 2005; 29: 166S-171.
30. Hines IN, Wheeler MD. Recent advances in alcoholic liver disease III. Role of the innate immune response in alcoholic hepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 287: G310-314.
31. McClain CJ, Hill DB, Song Z, Deaciuc I, Barve S. Monocyte activation in alcoholic liver disease. Alcohol 2002; 27: 53-61.
32. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003; 228: 882-890.
33. Thurman RG II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. 1998; 275: G605-611.
34. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 2002; 3: 932-943.
35. Danø K, Rømer J, Nielsen BS etal. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107: 120-127.
36. Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007; 177: 927-939.
37. Madsen CD, Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol. 2008; 87: 617-629.
38. Higazi AA, El-Haj M, Melhem A etal. Immunomodulatory effects of plasminogen activators on hepatic fibrogenesis. Clin. Exp. Immunol. 2008; 152: 163-173.
39. Koivisto H, Hietala J, Niemelä O. An inverse relationship between markers of fibrogenesis and collagen degradation in patients with or without alcoholic liver disease. Am. J. Gastroenterol. 2007; 102: 773-779.
40. Parkes J, Roderick P, Harris S etal. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-1251.
41. Sheron N, Moore M, Ansett S, Parsons C, Bateman A. Developing a "traffic light" test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Br. J. Gen. Pract. 2012; 62: e616-624.
42. Eugen-Olsen J, Andersen O, Linneberg A etal. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J. Intern. Med. 2010; 268: 296-308.
43. Klassen LW, Tuma D, Sorrell MF. Immune mechanisms of alcohol-induced liver disease. Hepatology 1995; 22: 355-357.
44. Marshall JB, Burnett DA, Zetterman RK, Sorrell MF. Clinical and biochemical course of alcoholic liver disease following sudden discontinuation of alcoholic consumption. Alcohol. Clin. Exp. Res. 1983; 7: 312-315.